$0.057
0[0.00%]
At close: Dec 29
Rubius Therapeutics Inc Com
(OTC:RUBY)Rubius Therapeutics Inc Com Stock (OTC:RUBY), Analyst Ratings, Price Targets, Predictions
Rubius Therapeutics Inc Com has a consensus price target of $7.1, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from Guggenheim, Morgan Stanley, and SVB Leerink on September 13, 2022, September 9, 2022, and August 9, 2022. With an average price target of $0.83 between Guggenheim, Morgan Stanley, and SVB Leerink, there's an implied 1361.99% upside for Rubius Therapeutics Inc Com from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Morgan Stanley
SVB Leerink
HC Wainwright & Co.
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Rubius Therapeutics Inc Com
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 09/13/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | — | Guggenheim | Michael Schmidt | — | Downgrade | Buy → Neutral | Get Alert |
| 09/09/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 2531.58% | Morgan Stanley | Jeffrey Hung | $2 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 08/09/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 1654.39% | SVB Leerink | Jonathan Chang | $2 → $1 | Maintains | Market Perform | Get Alert |
| 05/11/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 3408.77% | Morgan Stanley | Jeffrey Hung | $4 → $2 | Maintains | Equal-Weight | Get Alert |
| 05/11/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 13935.09% | HC Wainwright & Co. | Andrew Fein | $15 → $8 | Maintains | Buy | Get Alert |
| 05/10/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 5163.16% | SVB Leerink | Jonathan Chang | $2 → $3 | Maintains | Market Perform | Get Alert |
| 04/11/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 6917.54% | Morgan Stanley | Jeffrey Hung | $15 → $4 | Maintains | Equal-Weight | Get Alert |
| 04/11/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 8671.93% | Guggenheim | Michael Schmidt | $25 → $5 | Maintains | Buy | Get Alert |
| 04/11/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 26215.79% | HC Wainwright & Co. | Andrew Fein | $40 → $15 | Maintains | Buy | Get Alert |
| 04/11/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 5163.16% | SVB Leerink | Jonathan Chang | $5 → $3 | Maintains | Market Perform | Get Alert |
| 02/25/2022 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 8671.93% | SVB Leerink | Jonathan Chang | $14 → $5 | Maintains | Market Perform | Get Alert |
| 11/09/2021 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 24461.4% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
| 05/18/2021 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 43759.65% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
| 04/19/2021 | RUBY | Buy Now | Rubius Therapeutics | $0.06 | 42005.26% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Rubius Therapeutics Inc Com (RUBY)?
The latest price target for Rubius Therapeutics Inc Com (OTC: RUBY) was reported by Guggenheim on September 13, 2022. The analyst firm set a price target for $0.00 expecting RUBY to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rubius Therapeutics Inc Com (RUBY)?
The latest analyst rating for Rubius Therapeutics Inc Com (OTC: RUBY) was provided by Guggenheim, and Rubius Therapeutics Inc Com downgraded their neutral rating.
When was the last upgrade for Rubius Therapeutics Inc Com (RUBY)?
There is no last upgrade for Rubius Therapeutics Inc Com.
When was the last downgrade for Rubius Therapeutics Inc Com (RUBY)?
The last downgrade for Rubius Therapeutics Inc Com happened on September 13, 2022 when Guggenheim changed their price target from N/A to N/A for Rubius Therapeutics Inc Com.
When is the next analyst rating going to be posted or updated for Rubius Therapeutics Inc Com (RUBY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rubius Therapeutics Inc Com, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rubius Therapeutics Inc Com was filed on September 13, 2022 so you should expect the next rating to be made available sometime around September 13, 2023.
Is the Analyst Rating Rubius Therapeutics Inc Com (RUBY) correct?
While ratings are subjective and will change, the latest Rubius Therapeutics Inc Com (RUBY) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rubius Therapeutics Inc Com (RUBY) is trading at is $0.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.